Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hocanalysis of the Engage trial

Table 2 Estimated effect in percentage points (Δ) and associated 95% confidence interval (95% CI) of the covariates included in Model 1 and Model 2 on ongoing pregnancy rate

Factors included in model	Categories	Model 1*	Model 2^†
		Δ (95% CI)	Δ (95% CI)
Start treatment	Day 2 versus day 3	-4.3 (-9.4, 0.8)
hCG delay	No delay versus 1-day delay	1.8 (-4.1, 7.6)
rFSH on day of hCG	Yes versus no	3.2 (-2.1, 8.6)
rFSH from day 8	Step-down versus fixed dose		-5.8 (-13.0, 1.4)
Treatment group	Corifollitropin alfa versus rFSH	1.1 (-4.0, 6.2)	1.1 (-4.8, 6.9)
Age	Per year increase	-1.1 (-1.9, -0.3)	-0.9 (-1.8, 0.0)
Region	North America versus Europe	15.5 (10.2, 20.7)	12.6 (6.8, 18.5)

*Model 1 is based on Analysis Set 1, i.e., all patients who received hCG and for whom no rFSH dose was withheld for one or more consecutive days including the day of hCG.
^†Model 2 is based on Analysis Set 2, i.e., all patients who received hCG on or after day 9 and for whom no rFSH dose was withheld for one or more consecutive days from day 8 including the day of hCG.

ISSN: 1477-7827